Bullish On Anika Therapeutics's Pullback As Integrity Scales
Anika Therapeutics is refocusing on HA-based OA pain management and regenerative orthopedic products. The main drivers here are Monovisc, Orthovisc, and Integrity. Particularly, ANIK's Integrity received 510(k) clearance in 2023. Recently, its revenues have more than doubled in 2025. Hyalofast and Cingal also offer interesting regulatory catalysts, but they bring FDA timing and approval risks.
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript
Anika Therapeutics, Inc. ( ANIK ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Matt Hall Cheryl Blanchard - President, CEO & Director Stephen Griffin - Executive VP, CFO & COO Conference Call Participants Michael Petusky - Barrington Research Associates, Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Anika's third quarter earnings conference call. [Operator Instructions] I will now turn the call over to Matt Hall, Director, Corporate Development and Investor Relations.
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.25 per share a year ago.
Anika (ANIK) Upgraded to Buy: Here's What You Should Know
Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts
Anika Therapeutics is an HA-platform company with regenerative, OA pain, and non-orthopedic products. Their main line is called Integrity. But Hyalofast and Cingal can also eventually target the sizeable cartilage and OA markets. ANIK's Integrity outperformed since launch, and their regenerative solutions have grown YoY. That's why the company believes it can also tap into the tendon-augmentation TAM.
Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Cheryl Renee Blanchard - President, CEO & Director Matt Hall - Corporate Participant Stephen D. Griffin - Executive VP, CFO & COO Conference Call Participants Anderson Schock - B.
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.17 per share a year ago.
Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Anderson Schock - B. Riley Securities Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company.
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of $0.31 per share a year ago.
Is the Options Market Predicting a Spike in Anika Therapeutics Stock?
Investors need to pay close attention to ANIK stock based on the movements in the options market lately.
